The Connecticut Business & Industry Association is the voice of business in Connecticut, with thousands of member companies championing change at the State Capitol, shaping debate about economic competitiveness, and fighting for a better future for all.
The Connecticut Bioscience Growth Council consists of representatives from CBIA member companies with biotech, pharmaceutical, and bioscience-related interests.
It was organized to better address the issues affecting this growing sector, especially the importance of strong intellectual property protection and the industry's uniquely high R&D costs.
Working with CBIA staff, the council communicates to policymakers strategies to fuel industry job growth and timely introduction of new medicines, medical devices, and products developed and/or manufactured with the aid of bioscience.
The council will represent the interests of biotech and biopharma companies—large and small—at the State Capitol and regulatory agencies, providing greater advocacy support and resources, and developing an overall plan for better positioning these companies at the state, regional, and national level.
Council members meet regularly and interacts with the Connecticut General Assembly's Life Sciences Caucus and Connecticut's Congressional delegation.
The council is led by CBIA's Paul Pescatello.
As part of the council's advocacy efforts, Pescatello works to enhance and secure important policies, such as the research and development tax credit for both established and early-stage companies.
In addition to representing the biotech and biopharma industries at the state level, Pescatello serves as president of the New England Biotech Association, chairs We Work for Health Connecticut, and works closely with the Biotechnology Industry Organization.
Until the coronavirus pandemic ends, COVID testing will remain mandatory in some settings, which could be good news for a...
For biopharma, the Connecticut General Assembly is a major cause of cognitive dissonance—the discomfort caused by contradictory information. Over the...
Thriving biotech hubs are about collaboration—within companies, but just as important with scientists, research institutions, hospitals, managerial talent, and bankers...
More than 20 biotech and biopharma companies and organizations, including Connecticut’s Alexion, Boehringer Ingelheim, Sanofi, and Pfizer, are warning that...
The April issue of The Connecticut Economic Digest examines Connecticut’s bioscience industry and its impact on employment. Bioscience today spans...
The bioscience industry has hit back at wide-reaching drug price control proposals in Massachusetts and Connecticut that threaten sector innovation...